Piper Jaffray Remains Bullish Ahead of AmSurg's (AMSG) 4Q Release

Piper Jaffray maintained an Overweight rating on AmSurg (NASDAQ: AMSG), and cut the price target to $86.00 (from $90.00), ahead of the company's 4Q earnings release. Piper Jaffray expects the company's results to come in strong, due to Physician Services growth driven by recent acquisitions. AMSG is scheduled to report results on 2/24.

Analyst Kevin Ellich commented, "We expect AMSG to report good Q4 results next Wednesday (2/24) due to strong Physician Services growth driven by recent acquisitions. We believe the contribution from the three large acquisitions completed during the quarter will be enough to offset the dilution from the secondary offering completed in December. We expect steady Ambulatory Services results driven by 3% same-center growth and we are projecting 9% same contract growth in Physician Services. We updated our estimates for the secondary offering and the acquisitions completed during Q4, which we highlight below. We maintain our Overweight rating and we lowered our PT to $86 ($90 prior)."

For an analyst ratings summary and ratings history on AmSurg click here. For more ratings news on AmSurg click here.

Shares of AmSurg closed at $67.28 yesterday.

You May Also Be Interested In

• CIENA (CIEN) PT Raised to $600 at Raymond James
• Jefferies Resumes Ferguson Enterprises (FERG) at Buy
• CIENA (CIEN) PT Lowered to $520 at Needham, 'We would be buyers on weakness'